Ultrasound and CT Improve Nodal Staging in High-Risk cSCC

Moving Beyond the Physical Exam in cSCC Staging

For years, the physical examination has been a cornerstone of the initial assessment for patients with cutaneous squamous cell carcinoma (cSCC). However, emerging data suggests that relying solely on clinical palpation may leave a significant number of nodal metastases undetected, potentially delaying critical interventions.

Recent multicentre research involving 155 patients across 13 tertiary dermato-oncology centres in Spain has highlighted a stark contrast in diagnostic accuracy. While physical examinations are highly specific, their sensitivity in detecting nodal involvement is remarkably low, often missing early signs of regional spread that imaging can identify.

The Imaging Advantage: Ultrasonography and CT

The shift toward integrating imaging into routine staging is driven by the superior sensitivity of ultrasonography and computed tomography (CT). When compared, ultrasonography emerged as the most sensitive tool for detecting metastases at baseline, followed closely by contrast-enhanced CT.

Data indicates that ultrasonography achieved a sensitivity of 63.6%, while CT followed at 54.5%. Both modalities maintained high specificity, exceeding 95%. Due to the fact that these two imaging methods show strong agreement, they are increasingly viewed as interchangeable options depending on the available resources and the specific clinical context of the patient.

This trend suggests a future where baseline nodal assessment for high-risk cSCC is no longer a matter of “feeling” for enlarged nodes, but a standardized imaging protocol. This approach ensures that patients with high-risk skin cancer profiles receive a more accurate staging before surgery.

The Immunosuppression Gap: A Critical Challenge

One of the most significant revelations in recent dermato-oncology research is the “diagnostic divergence” based on a patient’s immune status. For immunocompetent patients, the future of staging looks promising: both ultrasonography and CT achieved 100% sensitivity, identifying every metastatic case at baseline.

However, the landscape changes drastically for immunosuppressed individuals. In this population, the sensitivity of ultrasonography plummeted to 20.0%, and CT dropped to 16.7%. This gap reveals a dangerous blind spot; nodal metastases in immunosuppressed patients often emerge rapidly during follow-up, even after initial imaging returns negative results.

Future Directions: Personalized Staging Protocols

The evidence points toward a move away from “one-size-fits-all” guidelines and toward personalized staging protocols. The goal is to tailor the intensity of surveillance based on the patient’s specific risk factors and immune profile.

Future clinical guidelines are likely to emphasize a stratified approach:

• For Immunocompetent Patients: A heavy reliance on baseline imaging (US or CT) to accurately stage the disease and plan surgical intervention.
• For Immunosuppressed Patients: A hybrid model that combines baseline imaging with aggressive, frequent follow-up intervals to catch rapidly evolving metastases.

By integrating these findings, the medical community can move toward a more individualized approach to cSCC management, ensuring that the most vulnerable patients do not fall through the diagnostic cracks. For more detailed academic insights, the full study can be found in JAMA Dermatology.

Frequently Asked Questions